



August 3, 2017

Aldeyra Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference

LEXINGTON, Mass., Aug. 3, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 37th Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2017.

Event: 37th Annual Canaccord Genuity Growth Conference

Date: Thursday, August 10, 2017

Time: 1:00 PM ET

Location: The InterContinental Hotel, Boston, MA

A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.

Corporate Contact:

Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com

Investor Contact:

Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com

Media Contact:

Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com

View original content: <http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-37th-annual-canaccord-genuity-growth-conference-300498958.html>

SOURCE Aldeyra Therapeutics, Inc.

News Provided by Acquire Media